Nanobiotix S.A.
NBTX
$3.39
$0.24117.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -9.47M | -9.77M | 3.32M | 3.35M | 16.18M |
| Total Other Revenue | 689.10K | 710.70K | 1.68M | 1.70M | 1.54M |
| Total Revenue | -8.78M | -9.06M | 5.00M | 5.04M | 17.72M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -8.78M | -9.06M | 5.00M | 5.04M | 17.72M |
| SG&A Expenses | 5.17M | 5.33M | 5.83M | 5.88M | 6.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.06M | 15.53M | 17.66M | 17.81M | 17.10M |
| Operating Income | -23.84M | -24.59M | -12.66M | -12.77M | 613.10K |
| Income Before Tax | -24.68M | -25.45M | -11.69M | -11.79M | -6.18M |
| Income Tax Expenses | -22.90K | -23.60K | 77.50K | 78.20K | 63.00K |
| Earnings from Continuing Operations | -24.66M | -25.43M | -11.77M | -11.87M | -6.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.66M | -25.43M | -11.77M | -11.87M | -6.24M |
| EBIT | -23.84M | -24.59M | -12.66M | -12.77M | 613.10K |
| EBITDA | -23.68M | -24.42M | -12.51M | -12.62M | 760.60K |
| EPS Basic | -0.52 | -0.54 | -0.25 | -0.25 | -0.16 |
| Normalized Basic EPS | -0.35 | -0.36 | -0.15 | -0.16 | -0.04 |
| EPS Diluted | -0.52 | -0.54 | -0.25 | -0.25 | -0.16 |
| Normalized Diluted EPS | -0.35 | -0.36 | -0.15 | -0.16 | -0.04 |
| Average Basic Shares Outstanding | 47.41M | 47.41M | 47.12M | 47.12M | 38.82M |
| Average Diluted Shares Outstanding | 47.41M | 47.41M | 47.12M | 47.12M | 38.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |